Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-3475-D46)

Merck Sharp & Dohme (MSD)

Status and phase: Enrolling; Phase 3

Conditions: Carcinoma, Non-Small-Cell Lung

Treatments: Biological: Pembrolizumab; Biological: Sacituzumab Govitecan

Study type: Interventional

Funder types: Industry

Identifiers

NCT05609968

2022-000836-49 (EudraCT Number)

PHRR230203-005387 (Registry Identifier)

3475-D46

jRCT2031230031 (Registry Identifier)

MK-3475-D46 (Other Identifier)

Details and patient eligibility

About

The purpose of this study is to compare pembrolizumab (MK-3475) in combination with sacituzumab govitecan with pembrolizumab alone with respect to progression-free survival (PFS) and overall survival (OS) per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by blinded independent central review (BICR) among adults with metastatic non-small cell lung cancer (NSCLC) with programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) ≥50%).

Enrollment: 614 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

• Has a histologically or cytologically confirmed diagnosis of metastatic non-small cell lung cancer (NSCLC)
• Has confirmation that epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase 1 (ALK-1), or ROS proto-oncogene 1 (ROS-1)-directed therapy is not indicated as primary therapy
• Has provided tumor tissue that demonstrates PD-L1 tumor proportion score (TPS) ≥50% of tumor cells as assessed by immunohistochemistry (IHC) at a central laboratory
• Has a life expectancy of at least 3 months

Exclusion criteria

The main exclusion criteria include but are not limited to the following:

• Has history of a second malignancy, unless potentially curative treatment has been completed with no evidence of malignancy for 3 years

• Has received prior systemic chemotherapy or other targeted or biological antineoplastic therapy for their metastatic NSCLC

• Has previously received treatment with Topoisomerase 1 inhibitors or Trop-2 targeted therapy

• Has received prior therapy with an anti-programmed cell death 1 protein (anti-PD-1), anti-programmed cell death ligand 1 (anti-PD-L1), or anti anti- programmed cell death ligand 2 (PD-L2) agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor

• Has received prior radiotherapy within 2 weeks of start of study intervention or has radiation-related toxicities requiring corticosteroids

• Has received radiation therapy to the lung that is >30 Gray (Gy) within 6 months of the first dose of study intervention

• Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention

• Has received an investigational agent or has used an investigational device within 4 weeks before study intervention administration

• Has cardiac disease

  • Myocardial infarction or unstable angina pectoris within 6 months of enrollment
  • History of serious ventricular arrhythmia, high-grade atrioventricular block, or other cardiac arrhythmias requiring antiarrhythmic medications; history of QT interval prolongation
  • New York Heart Association (NYHA) Class III or greater congestive heart failure or left ventricular ejection fraction of <40%

• Has active chronic inflammatory bowel disease

• Has diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior the first dose of study medication

• Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis

• Has severe hypersensitivity (≥Grade 3) to pembrolizumab or sacituzumab govitecan and/or any of their excipients

• Has active autoimmune disease that has required systemic treatment in past 2 years except replacement therapy

• History of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease

• Has active infection requiring systemic therapy

• Has history of human immunodeficiency virus (HIV) infection

• History of hepatitis B or known active hepatitis C virus infection

• Has history or current evidence of any condition, therapy, laboratory abnormality, or other circumstance that might confound the results of the study or interfere with the participant's participation for the full duration of the study, such that it is not in the best interest of the participant to participate, in the opinion of the treating investigator

• Have not adequately recovered from major surgery or have ongoing surgical complications

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

614 participants in 2 patient groups

Pembrolizumab + Sacituzumab Govitecan

Experimental group

Description:

Participants receive sacituzumab govitecan 10mg/kg intravenous (IV) infusion once weekly on Day 1 and Day 8 of a continuous 21-day cycle until progressive disease (PD) requiring discontinuation, unacceptable toxicity, withdrawal of consent, or death. Participants receive pembrolizumab 200mg IV infusion on Day 1 every 3 weeks (Q3W) for up to 35 cycles (each cycle length = 21 days).

Treatment:

Biological: Sacituzumab Govitecan

Biological: Pembrolizumab

Pembrolizumab

Experimental group

Description:

Participants receive pembrolizumab 200mg IV infusion on Day 1 Q3W for up to 35 cycles (each cycle length = 21 days).

Treatment:

Biological: Pembrolizumab